-
Je něco špatně v tomto záznamu ?
Visceral fat area and cardiometabolic risk: The Kardiovize study
A. Polcrova, I. Pavlovska, GA. Maranhao Neto, S. Kunzova, MM. Infante-Garcia, JR. Medina-Inojosa, F. Lopez-Jimenez, JI. Mechanick, R. Nieto-Martinez, GB. Stokin, H. Pikhart, JP. Gonzalez-Rivas
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- diabetes mellitus 2. typu * MeSH
- dospělí MeSH
- kardiovaskulární nemoci * epidemiologie etiologie MeSH
- lidé středního věku MeSH
- lidé MeSH
- metabolický syndrom * epidemiologie etiologie MeSH
- nitrobřišní tuk MeSH
- průřezové studie MeSH
- rizikové faktory MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
BACKGROUND: Visceral fat is associated with adiposity-based complications. Bioimpedance measurement allows estimation of visceral fat area (VFA) in an easy manner. However, a validated cut-off value for VFA by bioimpedance associated with cardiometabolic risk is lacking in European population. AIM: To determine cut-off values of VFA measured via bioimpedance associated with cardiometabolic risk. METHODS: Random cross-sectional Czech population-based sample of 25-64 years old subjects. Receiver Operating Characteristic (ROC) curves were used and the area under the curve (AUC), sensitivity, and specificity were calculated. The Cardiometabolic Disease Staging System (CMDS) was used to classify cardiometabolic risk: Stage 1 - 1 or 2 metabolic syndrome (MetS) components, without impaired fasting glucose (IFG); Stage 2 - MetS or IFG; Stage 3 - MetS with IFG; Stage 4 - type 2 diabetes and/or cardiovascular disease. RESULTS: 2052 participants (54.5% females, median age 49 years) were included. Median VFA (inter-quartile range) were 82.2 cm2 (54.8) in men and 89.8 cm2 (55.6) in women. The best VFA cut-offs associated with Stage 1 in men and women were 71 cm2 (sensitivity = 0.654; specificity = 0.427) and 83 cm2 (sensitivity = 0.705; specificity = 0.556) ; Stage 2: 84 cm2 (sensitivity = 0.673; specificity = 0.551) and 98 cm2 (sensitivity = 0.702; specificity = 0.628) ; Stage 3: 90 cm2 (sensitivity = 0.886; specificity = 0.605) and 109 cm2 (sensitivity = 0.755; specificity = 0.704); Stage 4: 91 cm2 (sensitivity = 0.625; specificity = 0.611) and 81 cm2 (sensitivity = 0.695; specificity = 0.448), respectively. CONCLUSION: A cut-off value of VFA of 71 cm2 in men and 83 cm2 in women exhibited the earliest stage of cardiometabolic risk, and 90 cm2 in men and 109 cm2 in women showed the best performance to detect risk.
Department of Epidemiology and Public Health University College London United Kingdom
Department of Public Health Faculty of Medicine Masaryk University Brno Czech Republic
Division of Preventive Cardiology Department of Cardiovascular Medicine Mayo Clinic USA
Foundation for Clinic Public Health and Epidemiology Research of Venezuela Caracas Venezuela
International Clinical Research Center Czech Republic
Research Centre for Toxic Compounds in the Environment Masaryk University Brno Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21025492
- 003
- CZ-PrNML
- 005
- 20241203101619.0
- 007
- ta
- 008
- 211013s2021 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.orcp.2021.03.005 $2 doi
- 035 __
- $a (PubMed)33744224
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Bartošková, Anna $u International Clinical Research Center (ICRC), St Anne's University Hospital Brno (FNUSA), Czech Republic; Research Centre for Toxic Compounds in the Environment (RECETOX), Masaryk University, Brno, Czech Republic. Electronic address: anna.polcrova@fnusa.cz $7 mub20241225433
- 245 10
- $a Visceral fat area and cardiometabolic risk: The Kardiovize study / $c A. Polcrova, I. Pavlovska, GA. Maranhao Neto, S. Kunzova, MM. Infante-Garcia, JR. Medina-Inojosa, F. Lopez-Jimenez, JI. Mechanick, R. Nieto-Martinez, GB. Stokin, H. Pikhart, JP. Gonzalez-Rivas
- 520 9_
- $a BACKGROUND: Visceral fat is associated with adiposity-based complications. Bioimpedance measurement allows estimation of visceral fat area (VFA) in an easy manner. However, a validated cut-off value for VFA by bioimpedance associated with cardiometabolic risk is lacking in European population. AIM: To determine cut-off values of VFA measured via bioimpedance associated with cardiometabolic risk. METHODS: Random cross-sectional Czech population-based sample of 25-64 years old subjects. Receiver Operating Characteristic (ROC) curves were used and the area under the curve (AUC), sensitivity, and specificity were calculated. The Cardiometabolic Disease Staging System (CMDS) was used to classify cardiometabolic risk: Stage 1 - 1 or 2 metabolic syndrome (MetS) components, without impaired fasting glucose (IFG); Stage 2 - MetS or IFG; Stage 3 - MetS with IFG; Stage 4 - type 2 diabetes and/or cardiovascular disease. RESULTS: 2052 participants (54.5% females, median age 49 years) were included. Median VFA (inter-quartile range) were 82.2 cm2 (54.8) in men and 89.8 cm2 (55.6) in women. The best VFA cut-offs associated with Stage 1 in men and women were 71 cm2 (sensitivity = 0.654; specificity = 0.427) and 83 cm2 (sensitivity = 0.705; specificity = 0.556) ; Stage 2: 84 cm2 (sensitivity = 0.673; specificity = 0.551) and 98 cm2 (sensitivity = 0.702; specificity = 0.628) ; Stage 3: 90 cm2 (sensitivity = 0.886; specificity = 0.605) and 109 cm2 (sensitivity = 0.755; specificity = 0.704); Stage 4: 91 cm2 (sensitivity = 0.625; specificity = 0.611) and 81 cm2 (sensitivity = 0.695; specificity = 0.448), respectively. CONCLUSION: A cut-off value of VFA of 71 cm2 in men and 83 cm2 in women exhibited the earliest stage of cardiometabolic risk, and 90 cm2 in men and 109 cm2 in women showed the best performance to detect risk.
- 650 _2
- $a dospělí $7 D000328
- 650 12
- $a kardiovaskulární nemoci $x epidemiologie $x etiologie $7 D002318
- 650 _2
- $a průřezové studie $7 D003430
- 650 12
- $a diabetes mellitus 2. typu $7 D003924
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a nitrobřišní tuk $7 D050152
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 12
- $a metabolický syndrom $x epidemiologie $x etiologie $7 D024821
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a rizikové faktory $7 D012307
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Pavlovska, Iuliia $u International Clinical Research Center (ICRC), St Anne's University Hospital Brno (FNUSA), Czech Republic; Department of Public Health, Faculty of Medicine, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Maranhao Neto, Geraldo A $u International Clinical Research Center (ICRC), St Anne's University Hospital Brno (FNUSA), Czech Republic
- 700 1_
- $a Kunzova, Sarka $u International Clinical Research Center (ICRC), St Anne's University Hospital Brno (FNUSA), Czech Republic
- 700 1_
- $a Infante-Garcia, Maria M $u Foundation for Clinic, Public Health, and Epidemiology Research of Venezuela (FISPEVEN INC), Caracas, Venezuela
- 700 1_
- $a Medina-Inojosa, Jose R $u Division of Preventive Cardiology, Department of Cardiovascular Medicine, Mayo Clinic, USA
- 700 1_
- $a Lopez-Jimenez, Francisco $u Division of Preventive Cardiology, Department of Cardiovascular Medicine, Mayo Clinic, USA
- 700 1_
- $a Mechanick, Jeffrey I $u The Marie-Josée and Henry R. Kravis Center for Cardiovascular Health at Mount Sinai Heart, and Division of Endocrinology, Diabetes and Bone Disease, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- 700 1_
- $a Nieto-Martinez, Ramfis $u Foundation for Clinic, Public Health, and Epidemiology Research of Venezuela (FISPEVEN INC), Caracas, Venezuela; Department of Global Health and Population, Harvard TH Chan School of Public Health, Harvard University, Boston, MA, USA; LifeDoc Health, Memphis, TN, USA
- 700 1_
- $a Stokin, Gorazd B $u International Clinical Research Center (ICRC), St Anne's University Hospital Brno (FNUSA), Czech Republic
- 700 1_
- $a Pikhart, Hynek $u Research Centre for Toxic Compounds in the Environment (RECETOX), Masaryk University, Brno, Czech Republic; Department of Epidemiology and Public Health, University College London, United Kingdom
- 700 1_
- $a Gonzalez-Rivas, Juan P $u International Clinical Research Center (ICRC), St Anne's University Hospital Brno (FNUSA), Czech Republic; Foundation for Clinic, Public Health, and Epidemiology Research of Venezuela (FISPEVEN INC), Caracas, Venezuela; Department of Global Health and Population, Harvard TH Chan School of Public Health, Harvard University, Boston, MA, USA
- 773 0_
- $w MED00167310 $t Obesity research & clinical practice $x 1871-403X $g Roč. 15, č. 4 (2021), s. 368-374
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33744224 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20211013 $b ABA008
- 991 __
- $a 20241203101616 $b ABA008
- 999 __
- $a ok $b bmc $g 1714517 $s 1145999
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 15 $c 4 $d 368-374 $e 20210318 $i 1871-403X $m Obesity research & clinical practice $n Obes Res Clin Pract $x MED00167310
- LZP __
- $a Pubmed-20211013
